| Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma O Van Oekelen, CR Gleason, S Agte, K Srivastava, KF Beach, A Aleman, ... Cancer Cell 39 (8), 1028-1030, 2021 | 209 | 2021 |
| Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy O Van Oekelen, A Aleman, B Upadhyaya, S Schnakenberg, D Madduri, ... Nature medicine 27 (12), 2099-2103, 2021 | 130 | 2021 |
| The congenital heart disease genetic network study: cohort description TT Hoang, E Goldmuntz, AE Roberts, WK Chung, JK Kline, JE Deanfield, ... PloS one 13 (1), e0191319, 2018 | 95 | 2018 |
| Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma A Aleman, B Upadhyaya, K Tuballes, K Kappes, CR Gleason, K Beach, ... Cancer Cell 39 (11), 1442-1444, 2021 | 74 | 2021 |
| Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications S Bhalla, DT Melnekoff, A Aleman, V Leshchenko, P Restrepo, J Keats, ... Science Advances 7 (47), eabg9551, 2021 | 60 | 2021 |
| Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy O Van Oekelen, K Nath, TH Mouhieddine, T Farzana, A Aleman, ... Blood 141 (7), 756-765, 2023 | 53 | 2023 |
| Myeloma CAR-T CRS management with IL-1R antagonist anakinra SS Jatiani, A Aleman, D Madduri, A Chari, HJ Cho, S Richard, J Richter, ... Clinical Lymphoma Myeloma and Leukemia 20 (9), 632-636. e1, 2020 | 36 | 2020 |
| Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma DH Vesole, E Bilotti, JR Richter, A McNeill, L McBride, L Raucci, P Anand, ... British journal of haematology 171 (1), 52-59, 2015 | 34 | 2015 |
| Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients A Aleman, O Van Oekelen, B Upadhyaya, K Beach, AK Zajdman, ... Cancer Cell 40 (5), 441-443, 2022 | 32 | 2022 |
| Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma TH Mouhieddine, O Van Oekelen, DT Melnekoff, J Li, Y Ghodke-Puranik, ... Blood advances 7 (6), 1056-1064, 2023 | 29 | 2023 |
| Comprehensive characterization of prolonged unexplained cytopenias in relapsed/refractory multiple myeloma patients following BCMA-directed CAR-T cell therapy S Thibaud, MB Mia, O Van Oekelen, TH Mouhieddine, C Schaniel, ... Blood 140 (Supplement 1), 614-616, 2022 | 20 | 2022 |
| A three-gene signature predicts response to selinexor in multiple myeloma P Restrepo, S Bhalla, Y Ghodke-Puranik, A Aleman, V Leshchenko, ... JCO Precision Oncology 6, e2200147, 2022 | 13 | 2022 |
| Kogan Zajdman A, Alshammary H, et al. Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients A Aleman, O Van Oekelen, B Upadhyaya, K Beach Cancer Cell 40 (5), 441-3, 2022 | 12 | 2022 |
| PVI/Seronet team; Mouhieddine, TH; Wang, B.; et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma O Van Oekelen, CR Gleason, S Agte, K Srivastava, KF Beach, A Aleman, ... Cancer Cell 39, 1028-1030, 2021 | 8 | 2021 |
| Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients A Aleman, O Van Oekelen, B Upadhyaya, S Agte, K Kappes, K Beach, ... MedRxiv, 2021.05. 15.21256814, 2021 | 7 | 2021 |
| Clinical outcomes and treatment strategies for relapsed/refractory myeloma patients after relapse on BCMA-targeted CAR T O Van Oekelen, TH Mouhieddine, D Pan, M Metzger, S Agte, A Aleman, ... Blood 138, 2704, 2021 | 6 | 2021 |
| Single-cell profiling reveals contribution of tumor extrinsic and intrinsic factors to BCMA-targeted CAR-T cell efficacy in multiple myeloma DT Melnekoff, Y Ghodke-Puranik, O Van Oekelen, A Aleman, ... Blood 138, 326, 2021 | 6 | 2021 |
| A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM). DH Vesole, DSDC Siegel, JR Richter, A McNeill, P Anand, U Bednarz, ... Journal of Clinical Oncology 32 (15_suppl), 8535-8535, 2014 | 6 | 2014 |
| Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial B Gordon, L Fogel, G Varma, MM Saldarriaga, J Ahn, A Aleman, J Caro, ... Blood 142, 4741, 2023 | 3 | 2023 |
| A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements RJ Kimmerling, MM Stevens, S Olcum, A Minnah, M Vacha, R LaBella, ... Communications Biology 5 (1), 1295, 2022 | 3 | 2022 |
